Jason S Burch

US Patent:

20110245296, Oct 6, 2011

Filed:

Mar 28, 2011

Appl. No.:

13/073631

Inventors:

Jason Burch - Redwood City CA, US
Bernard Cote - Notre-Dame-de-l'lie-Perrot, CA
Natalie Nguyen - Monteal, CA
Chun Sing Li - Dollard-Des-Ormeaux, CA
Miguel St-Onge - Vaudreuil-Dorion, CA
Danny Gauvreau - Saint-Lazare, CA

International Classification:

A61K 31/4439
C07D 401/06
A61P 31/18

US Classification:

514340, 5462724

Abstract:

Heteroaromatic compounds of Formula I:are HIV reverse transcriptase inhibitors, wherein R, R, R, Rand Rare defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

US Patent:

20110275660, Nov 10, 2011

Filed:

Sep 22, 2009

Appl. No.:

13/120786

Inventors:

Carl Berthelette - Laval, CA
Michael Boyd - Saint -Lazare, CA
Jason Burch - Redwood City CA, US
Claude Dufresne - Dollard-des-Ormeaux, CA
Julie Farand - Jersey NJ, US
Yongxin Han - Kirkland, CA
Claudio F. Sturino - Ile-Bizard, CA

International Classification:

A61K 31/437
A61K 31/444
A61P 9/10
A61P 25/00
A61P 19/06
C07D 471/04
A61P 29/00

US Classification:

514292, 546 86

Abstract:

The invention is directed to β-carboline sulphonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, inflammation, osteoarthritis, and rheumatoid arthritis. Pharmaceutical compositions and methods of use are also included.

US Patent:

20170210724, Jul 27, 2017

Filed:

Apr 7, 2017

Appl. No.:

15/481852

Inventors:

- South San Francisco CA, US
Georgette Castanedo - Redwood City CA, US
Jianwen A. Feng - Millbrae CA, US
Baihua Hu - Plainsboro NJ, US
Steven Staben - San Francisco CA, US
Guosheng Wu - Beijing, CN
Xingyu Lin - Beijing, CN
Jason Burch - Redwood City CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07D 401/10
C07D 401/14
C07D 491/107
C07D 409/14
C07D 405/14
C07D 495/04
C07D 495/06
C07D 471/04
C07D 487/04
C07D 413/10
C07D 403/10
C07D 405/10
C07D 417/14
C07D 491/048
C07D 413/14

Abstract:

The invention relates to compounds of Formula (0):wherein A-A, Rand Reach has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

US Patent:

20170145034, May 25, 2017

Filed:

Feb 6, 2017

Appl. No.:

15/425698

Inventors:

- South San Francisco CA, US
Georgette Castanedo - Redwood City CA, US
Jianwen A. Feng - Millbrae CA, US
Baihua Hu - Plainsboro NJ, US
Steven Staben - San Francisco CA, US
Guosheng Wu - Beijing, CN
Jason Burch - Redwood City CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07D 513/04
C07D 401/14
C07D 491/052
C07D 471/04
C07D 413/10
C07D 491/048
C07D 403/14
C07D 413/14
C07D 495/04
C07D 487/04
C07D 417/10
C07D 403/10
C07D 401/10

Abstract:

The invention relates to compounds of Formula (0):wherein Q, A-A, Rand Rand each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

US Patent:

20160200739, Jul 14, 2016

Filed:

Mar 18, 2016

Appl. No.:

15/074100

Inventors:

- South San Francisco CA, US
Georgette Castanedo - Redwood City CA, US
Jianwen A. Feng - Millbrae CA, US
Baihua Hu - Plainsboro NJ, US
Steven Staben - San Francisco CA, US
Guosheng Wu - Beijing, CN
Jason Burch - Redwood City CA, US

Assignee:

Genentech, Inc. - South San Francisco

International Classification:

C07D 513/04
C07D 401/14
C07D 413/14
C07D 471/04
C07D 413/10
C07D 401/10
C07D 403/10
C07D 491/052

Abstract:

The invention relates to compounds of Formula (0):

US Patent:

20160185797, Jun 30, 2016

Filed:

Mar 3, 2016

Appl. No.:

15/060325

Inventors:

- South San Francisco CA, US
Georgette Castanedo - Redwood City CA, US
Jianwen A. Feng - Millbrae CA, US
Baihua Hu - Plainsboro NJ, US
Steven Staben - San Francisco CA, US
Guosheng Wu - Beijing, CN
Xingyu Lin - Beijing, CN
Jason Burch - Redwood City CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07D 495/04
C07D 403/10
C07D 403/14
C07D 491/107
C07D 409/14
C07D 417/14
C07D 487/04
C07D 401/14
C07D 471/04
C07D 413/10
C07D 405/10
C07D 401/10
C07D 405/14

Abstract:

The invention relates to compounds of Formula (0):wherein A-A, Rand Reach has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

US Patent:

20160096850, Apr 7, 2016

Filed:

Aug 22, 2014

Appl. No.:

14/466153

Inventors:

- South San Francisco CA, US
Georgette Castanedo - Redwood City CA, US
Jianwen A. Feng - Millbrae CA, US
Baihua Hu - Plainsboro NJ, US
Steven Staben - San Francisco CA, US
Guosheng Wu - Beijing, CN
Jason Burch - Redwood City CA, US

Assignee:

GENENTECH, INC. - South San Francisco CA

International Classification:

C07D 513/04
C07D 471/04
C07D 403/10
C07D 401/14
C07D 413/10
C07D 491/052
C07D 487/04
C07D 401/10

Abstract:

The invention relates to compounds of Formula (0):Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

US Patent:

20150057260, Feb 26, 2015

Filed:

Aug 22, 2014

Appl. No.:

14/466176

Inventors:

- South San Francisco CA, US
Georgette Castanedo - Redwood City CA, US
Jianwen A. Feng - Millbrae CA, US
Baihua Hu - Plainsboro NJ, US
Steven Staben - San Francisco CA, US
Guosheng Wu - Beijing, CN
Xingyu Lin - Beijing, CN
Jason Burch - Redwood City CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07D 495/04
C07D 403/10
C07D 405/14
C07D 409/14
C07D 491/107
C07D 403/14
C07D 401/10

US Classification:

5142102, 5142358, 51425219, 514256, 5142601, 5142662, 514343, 544122, 544278, 544283, 544295, 544329, 544333, 544335, 5462787

Abstract:

The invention relates to compounds of Formula (0):wherein A-A, Rand Reach has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.